SCHEMBL6776310

SCHEMBL6776310

CSCC[C@H](NC(=O)OC(C)(C)C)C(N)=S

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CTSK P43235 4/20 0.60
CTSS P25774 3/20 0.60
CA2 P00918 1/20 0.49
HSD17B10 Q99714 1/20 0.46
TSHR P16473 1/20 0.46
EPHX2 P34913 1/20 0.44
KDM4E B2RXH2 4/20 0.42
ALDH1A1 P00352 4/20 0.42
MAPT P10636 1/20 0.42
KLK7 P49862 1/20 0.42
LMNA P02545 2/20 0.40
HPGD P15428 2/20 0.40
THRB P10828 1/20 0.40
KLK5 Q9Y337 1/20 0.40
CYP1A2 P05177 1/20 0.40
CYP2C9 P11712 1/20 0.40
CYP2C19 P33261 1/20 0.40
HTT P42858 1/20 0.40
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6623782 0.88 CTSK (0.63) CTSKCTSSCA2HSD17B10TSHR
SCHEMBL6623780 0.88 CTSK (0.63) CTSKCTSSCA2HSD17B10TSHR
SCHEMBL5717952 0.88 CTSK (0.63) CTSKCTSSCA2HSD17B10TSHR
SCHEMBL13778725 0.83 CTSK (0.64) CTSKCTSSCA2HSD17B10TSHR
SCHEMBL8203738 0.83 CTSK (0.64) CTSKCTSSCA2HSD17B10TSHR
SCHEMBL478905 0.83 CTSS (0.68) CTSKCTSSCA2TSHREPHX2
SCHEMBL4395744 0.83 CTSS (0.68) CTSKCTSSCA2TSHREPHX2
SCHEMBL15081482 0.83 CTSK (0.64) CTSKCTSSCA2HSD17B10TSHR
SCHEMBL352156 0.83 CTSS (0.68) CTSKCTSSCA2TSHREPHX2
SCHEMBL27483577 0.83 CTSK (0.64) CTSKCTSSCA2HSD17B10TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6693123-B2 (4-(3-PYRIDYLAMINOMETHYLENE)-2-PHENYLBENZOYL)-N -METHYLMETHIONINE, METHYL ESTER FOR EXAMPLE; RESTENOSIS, HYPERPLASIA UNIVERSITY OF PITTSBURGH 2004-02-17 US disclosed
US-20020193596-A1 Inhibitors of protein isoprenyl transferases UNIVERSITY OF PITTSBURGH (US) 2002-12-19 US disclosed
EP-0873123-A4 INHIBITORS OF PROTEIN ISOPRENYL TRANSFERASES UNIV PITTSBURGH (US) 1999-02-03 EP disclosed
EP-0873123-A1 INHIBITORS OF PROTEIN ISOPRENYL TRANSFERASES UNIVERSITY OF PITTSBURGH (US) 1998-10-28 EP disclosed
WO-1997017070-A1 INHIBITORS OF PROTEIN ISOPRENYL TRANSFERASES UNIVERSITY OF PITTSBURGH (US) 1997-05-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020193596-A1 Inhibitors of protein isoprenyl transferases LANCL1, FNTB, DHCR7 CTSK 3512/4885CTSS 3234/4885CA2 2452/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.